


Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 028622/0102		SERIAL NO. 09/673,735	
INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				APPLICANT Bernd DORKEN et al.			
				FILING DATE December 27, 2000		GROUP ART UNIT Unassigned	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
Pkt	A1 ✓	195 31 348	2/27/97	Fed. Republic of Germany			X
	A2 ✓	0 505 908	9/30/92	Europe			
	A3 ✓	91/09968	7/11/91	WIPO			
	A4 ✓	95/11922	5/4/95	WIPO			
	A5 ✓	96/36360	11/21/96	WIPO			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
Pkt	A6 ✓	H. Bohlen et al., "TREATMENT OF EB-VIRUS INDUCED B-CELL LCL IN SCID-HU MICE USING CD3XCD19 BISPECIFIC AND CD28 ANTIBODIES.", Proceedings of the American Association for Cancer Research, vol. 35, March, 1994, pg. 510, XP-002076122, abstract.					
	A7 ✓	Jan De Jonge et al., "Bispecific antibody treatment of murine B cell lymphoma.", Cancer Immunology Immunotherapy, vol. 45, No. 3/4, pp. 162-165, XP-002076120, Springer-Verlag, 1997					
	A8 ✓	Sergey M. Kiprianov et al., "BISPECIFIC CD3 X CD19 DIABODY FOR T-CELL-MEDIATED LYSIS OF MALIGNANT HUMAN B CELLS.", International Journal of Cancer, vol. 77, August 31, 1998, pp. 763-772, XP-002115487, Wiley-Liss, Inc., 1998					
	A9 ✓	P. Kufer et al., "Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer.", Cancer Immunology Immunotherapy, vol. 45, No. 3/4, pp. 193-197, XP-002076121, Springer-Verlag, 1997					
	A10 ✓	Anja Schroder et al., "A RECOMBINANT BISPECIFIC SINGLE CHAIN ANTIBODY CD19XCD3 INDUCED RAPID B CELL LYMPHOMA-DIRECTED CYTOTOXICITY OF UNSTIMULATED HUMAN T CELLS.", 40th Annual Meeting Of The American Society Of Hematology Miami Beach, Florida, December 4-8, 1998, XP-002115457, abstract.					
EXAMINER 				DATE CONSIDERED 9/19/05			
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.							


Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/P 10 INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: March 28, 2005 (use as many sheets as necessary)				Complete if Known Application Number 09/673,735 Filing Date 12/27/2000 First Named Inventor Bernd DORKEN Group Art Unit 1642 Examiner Name Larry Ronald Helms Attorney Docket Number 028622-0102	
Sheet	1	of	2		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

[illegible]

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
PkT	D1	ANDERSON, P. M., et al., "G19.4(αCD3) x B43(αCD19) Monoclonal Antibody Heteroconjugate Triggers CD19 Antigen-Specific Lysis of t(4;11) Acute Lymphoblastic Leukemia Cells by Activated CD3 Antigen-Positive Cytotoxic T Cells, Blood, vol. 80, no. 11, pp. 2826-2834 (1992).	
	D2	BOHLEN, H., et al., "Cytolysis of Leukemic B-Cells by T-Cells Activated via Two Bispecific Antibodies", Cancer Research, vol. 53, pp. 4310-4314 (1993).	
	D3	HAAGEN, I., et al., "Killing of Autologous B-Lineage Malignancy Using CD3 x CD19 Bispecific Monoclonal Antibody in End Stage Leukemia and Lymphoma", Blood, vol. 84, no. pp. 556-563 (1994).	
	D4	HAAGEN, I., et al., "Unprimed CD4+ and CD8+ T cells can be rapidly activated by a CD3 x CD19 bispecific antibody to proliferate and become cytotoxic", Cancer Immunol. Immunother, vol. 39, pp. 391-396 (1994).	
	D5	DE GAST, G. C., et al., "Clinical Experience with CD3 x CD 19 Bispecific Antibodies in Patients with B Cell Malignancies", J. Hema., vol. 4, pp. 433-437 (1995).	

Examiner Signature		Date Considered	7/19/05
-----------------------	---	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

MAR 28 2005

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: March 28, 2005

(use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number	09/673,735
Filing Date	12/27/2000
First Named Inventor	Bernd DORKEN
Group Art Unit	1642
Examiner Name	Larry Ronald Helms
Attorney Docket Number	028622-0102

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
PKT	D6	WEINER, G. J., et al., "Bispecific Monoclonal Antibody Therapy of B-Cell Malignancy", Leukemia and Lymphoma, vol. 16, pp. 199-207 (1995).	
	D7	HAAGEN, I., "Performance of CD3 x CD19 Bispecific Monoclonal Antibodies in B Cell Malignancy", Leukemia and Lymphoma, vol. 19, pp. 381-393 (1995)	
	D8	HAAGEN, I., et al., "The Efficacy of CD3 x CD19 Bispecific Monoclonal Antibody (BsAb) in a Clonogenic Assay: The Effect of Repeated Addition of BsAb and Interleukin-2", Blood, vol. 85, no. 11, pp. 3208-3212 (1995).	
	D9	MACK, M., et al., "A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity", Pro. Natl. Acad. Sci., vol. 92, pp. 7021-7025 (1995).	
	D10	KIPRIYANOV, S. M., et al., "Bispecific diabody for lysis of human B-lineage leukemia cells", The Fourteenth International Conf. on Adv. In the Application of Monoclonal Antibodies in Clinical Oncology", p. 29 Thira Santorini, Greece (May 5-7, 1997).	
	D11	DE JONGE J., et al., "Bispecific antibody treatment of murine B cell lymphoma", Cancer Immunol. Immunother, vol. 45, pp. 162-165 (1997).	
	D12	KUFER, P., et al., "Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer", Cancer Immunol. Immunother, vol. 45, pp. 193-197 (1997).	
	D13	KIPRIYANOV, S. M., et al., "Bispecific CD3 x CD 19 Diabody for T Cell-Mediated Lysis of Malignant Human B Cells", Int. J. Cancer, vol. 77, pp. 763-772 (1998).	

Examiner
Signature

P. G. [Signature]

Date
Considered


7/19/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/673,735
		Filing Date	12/27/2000
		First Named Inventor	Bernd DORKEN
		Group Art Unit	1642
		Examiner Name	Larry Ronald Helms
Sheet	1	of	2
		Attorney Docket Number	028622-0102

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
PKT	D1	ANDERSON, P. M., et al., "G19.4(αCD3) x B43(αCD19) Monoclonal Antibody Heteroconjugate Triggers CD19 Antigen-Specific Lysis of t(4;11) Acute Lymphoblastic Leukemia Cells by Activated CD3 Antigen-Positive Cytotoxic T Cells, Blood, vol. 80, no. 11, pp. 2826-2834 (1992).	
	D2	BOHLEN, H., et al., "Cytolysis of Leukemic B-Cells by T-Cells Activated via Two Bispecific Antibodies", Cancer Research, vol. 53, pp. 4310-4314 (1993).	
	D3	HAAGEN, I., et al., "Killing of Autologous B-Lineage Malignancy Using CD3 x CD19 Bispecific Monoclonal Antibody in End Stage Leukemia and Lymphoma", Blood, vol. 84, no. pp. 556-563 (1994).	
	D4	HAAGEN, I., et al., "Unprimed CD4+ and CD8+ T cells can be rapidly activated by a CD3 x CD19 bispecific antibody to proliferate and become cytotoxic", Cancer Immunol. Immunother, vol. 39, pp. 391-396 (1994).	
	D5	DE GAST, G. C., et al., "Clinical Experience with CD3 x CD 19 Bispecific Antibodies in Patients with B Cell Malignancies", J. Hema., vol. 4, pp. 433-437 (1995).	
	D6	WEINER, G. J., et al., "Bispecific Monoclonal Antibody Therapy of B-Cell Malignancy", Leukemia and Lymphoma, vol. 16, pp. 199-207 (1995).	
	D7	HAAGEN, I., "Performance of CD3 x CD19 Bispecific Monoclonal Antibodies in B Cell Malignancy", Leukemia and Lymphoma, vol. 19, pp. 381-393 (1995)	
	D8	HAAGEN, I., et al., "The Efficacy of CD3 x CD19 Bispecific Monoclonal Antibody (BsAb) in a Clonogenic Assay: The Effect of Repeated Addition of BsAb and Interleukin-2", Blood, vol. 85, no. 11, pp. 3208-3212 (1995).	
	D9	MACK, M., et al., "A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity", Pro. Natl. Acad. Sci., vol. 92, pp. 7021-7025 (1995).	
	D10	KIPRIYANOV, S. M., et al., "Bispecific diabody for lysis of human B-lineage leukemia cells", The Fourteenth International Conf. on Adv. In the Application of Monoclonal Antibodies in Clinical Oncology", p. 29 Thira Santorini, Greece (May 5-7, 1997).	


Examiner Signature		Date Considered	7/19/05
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number	09/673,735
Filing Date	12/27/2000
First Named Inventor	Bernd DORKEN
Group Art Unit	1642
Examiner Name	Larry Ronald Helms
Attorney Docket Number	028622-0102

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Pkt	D11	DE JONGE J., et al., "Bispecific antibody treatment of murine B cell lymphoma", Cancer Immunol. Immunother, vol. 45, pp. 162-165 (1997).	
	D12	KUFER, P., et al., "Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer", Cancer Immunol. Immunother, vol. 45, pp. 193-197 (1997).	
	D13	KIPRIYANOV, S. M., et al., "Bispecific CD3 x CD 19 Diabody for T Cell-Mediated Lysis of Malignant Human B Cells", Int. J. Cancer, vol. 77, pp. 763-772 (1998).	

Examiner
SignatureDate
Considered

2/19/5

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.